The Efficacy of Bromocriptine in Benign Prostatic Hypertrophy: A Double‐blind Study

Abstract

The efficacy and the safety of bromocriptine 7.5 mg daily were investigated in a double-blind versus placebo trial in 32 patients with troublesome symptoms from benign prostatic hypertrophy. Differences between the treatments in respect of uroflowmetry, residual urine and safety parameters were not statistically significant. Differences in respect of nocturia, daytime frequency and overall efficacy were statistically significant in favour of bromocriptine. There could be a place for bromocriptine in the palliative treatment of the functional disability caused by benign prostatic hypertrophy when surgery is refused or contraindicated.

Bromocriptine therapy: Review of mechanism of action, safety and tolerability

“…A study conducted in males suffering from BPH suggested that bromocriptine has a place in treating unstable bladder. 151,152 Del Pozo et al 153 in their study, reported a reduction in prolactin concentration after 6 to 8 hours of bromocriptine administration. Another study conducted by Polleri et al 154 also reported a reduction in the concentration of prolactin following the bromocriptine administration to men and women at 2.5 mg doses.…”

“…On the basis of such hypothesis, the central prolactin antagonist bromocriptine has been tested in clinical trials for its efficacy as well as safety in patients with symptoms of BPH. A study conducted in males suffering from BPH suggested that bromocriptine has a place in treating unstable bladder 151,152 . Del Pozo et al 153 in their study, reported a reduction in prolactin concentration after 6 to 8 hours of bromocriptine administration.…”

“…The therapeutic role of bromocriptine has been tried to verify successfully by various clinical trials conducted in different times for the management of PPCM, 102,104 adenomas, 124 mastalgia, 142,143 BPH, 152 and various autoimmune diseases 331,335,340,376,377 . Additionally, in vitro testing and computer aided studies have indicated the importance of bromocriptine for MPS IVA, 341 Chagas disease 353 and COVID‐19 369,370 .…”

“…130,221,223 Furthermore, off label use of bromocriptine has been reported for the treatment of Cushing's disease, 281 OHSS 32 and researchers also suggest bromocriptine as an effective adjunct agent in various cancer treatment protocols. 282,296 304,308 310 The therapeutic role of bromocriptine has been tried to verify successfully by various clinical trials conducted in different times for the management of PPCM, 102,104 adenomas, 124 mastalgia, 142,143 BPH, 152 and various autoimmune diseases. 331,335,340,376,377 Additionally, in vitro testing and computer aided studies have indicated the importance of bromocriptine for MPS IVA, 341 Chagas disease 353 and COVID-19.…”